How is the efficacy of patient selection criteria of KEYNOTE 564 for adjuvant pembrolizumab after curative surgical treatment of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience

ERDEM S., Tantekin A., Ozervarli F., ERGÜL R. B., Pazir Y., HÜRDOĞAN Ö., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.36, 2025 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 36
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.annonc.2025.08.3271
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • İstanbul Üniversitesi Adresli: Evet